Risk factors for myocardial infarction in HIV-positive patients

International Journal of STD and AIDS

Volumn 16, Issue 1, 2005, Pages 14-18

  Quiros Roldan, Eugenia ^a   Torti, C ^a   Tinelli, C ^a   Moretti, F ^a   Zanini, B ^a   Tirelli, V ^a   Pan, A ^a   Casari, S ^a   Carosi, G ^a  

^a NONE

Author keywords

Antiretroviral therapy; HIV; Infarction; Protease inhibitor; Risk factors

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CORONARY RISK; FAMILY HISTORY; FEMALE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; RNA, VIRAL;

EID: 13244275347     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462052932665     Document Type: Article

References (18)

1. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3
2. Mallon PW, Carr A, Cooper DA. HIV-associated lipodystrophy: description, pathogenesis and molecular pathways. Clin Diabetic Rep 2002;2:116-24
3. Reaven G, Segal K, Hanptman J, et al. Effect of orlistat assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001;87:827-31
4. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery and human immunodeficiency virus infection. Clin Infect Dis 2000;31:787-97
5. Paton P, Tabib A, Loire R, et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144:225-31
6. Joshi W, Pawel B, Connor E, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987;7:261-75
7. Carosi G, Castelli F, Suter F, et al. Antiviral potency of HAART regimens and clinical success are not study coupled in real life conditions: evidence from the MASTER-1 study. HIV Clin Trials 2001;25:399-407
8. WHO MONICA Project. MONICA Manual, Part IV: Event Registration Available at: [www.ktl.fi/publications/monica/manual/index.htm] (accessed 22 September 2002)
9. Dupont WD. Power calculations for matched case-control studies. Biometrics 1988;44:1157-68
10. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328
11. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8
12. Friis-Moller N, Weber R, D'Arminio Monforte A, et al. Exposure to HAART is associated with an increased risk of myocardial infarction. 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston. (Abstract number 130 [ses 26])
13. Klein D, Hurley L. Hospitalizations for coronary heart disease and myocardial infarction among HIV+ patients in the HAART era. Ninth Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, WA. (Abstract number 696-T [ses 91])
14. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10
15. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Inf Dis 2002;34:98-102
16. Hsue P, Lo J, Franklin A, Bolger AF, Deeks S, Walters D. Increased atherosclerotic progression in patients with HIV: the role of traditional and immunologic risk factors. 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February, 2003, Boston. (Abstract number 139Ib [ses 26])
17. Smiela M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107:251-7
18. Law M, Friis-Moller N, Weber R, et al. Modelling the 3-years risk of myocardial infaction among participants in the Data Collection on Adverse Events of Anti-HIV Drug (DAD) Study. HIV Med 2003;4:1-10